Contents - Pharma Technology Focus | Issue 138

Go to article: Home | Pharma’s path to Net Zero: Targeting Scope 3 emissions

Go to article: Editor's letter

Go to article: Contents

Go to article: Mimotopes Company Insight

Go to article: Mimotopes

Go to article: Briefing

Go to article: News in Numbers

Go to article: Latest News

Go to article: Latest Deals

Go to article: Project Updates

Go to article: Dycem

Go to article: In Depth

Go to article: Pharma’s path to Net Zero: Targeting Scope 3 emissions

Go to article: Profit vs inquiry: Clash of objectives in academic and commercial trials

Go to article: CTO Europe 2023: A snapshot of challenges and opportunities in oncology

Go to article: The future of cell and gene therapy manufacturing

Go to article: VPAS is dead, long live VPAG

Go to article: Q&A: European Pharmaceutical legislation: hindrance or help?

Go to article: Natoli

Go to article: Nipro

Go to article: Yearbook

Go to article: Yearbook contents

Go to article: UK’s pharma regulatory scene reckons with changes in 2023

Go to article: Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023

Go to article: Top themes of 2023: AI, precision medicine, virtual care, digital therapeutics

Go to article: Humira biosimilars set the stage for long-awaited 2023 US launches

Go to article: Inside the hunt for an Alzheimer’s disease vaccine

Go to article: Pathbreakers: The journey of first generics

Go to article: NASH drugs race to cross the finish line

Go to article: Fighting AMR with a value and subscription model

Go to article: Cancer treatment uncertainty: European nations struggle with drug shortages

Go to article: Why are haemophilia gene therapies so expensive?

Go to article: Top themes for the healthcare sector in 2024

Go to article: Listings

Go to article: Events

Go to article: The top 100 most innovative companies in the US in 2023

Go to article: Buyer's Guides

Go to article: Next issue